The report "Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products" helps to understand the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.
The FLD pipeline is relatively large, with 173 products in active development, which constitutes almost one fifth of the pipeline for the gastrointestinal therapy area. Many pipeline products for FLD are also in development for other non-hepatic fibrotic diseases or indications from the metabolic disorders therapy area - such as diabetes mellitus and dyslipidemia - reflecting the similarities in the underlying pathophysiology of these indications.
Strategic consolidation activity levels are relatively low in the FLD market, as reflected in the low number of licensing and co-development deals completed since 2006. Analysis of licensing and co-development deals relating to FLD therapeutics since 2006 has identified aggregate deal values of $778m and $1.8 billion, respectively.
Due to the increasing prevalence and the health burden of FLD, and the lack of therapeutic options, there is a high need to develop pharmacological strategies. This is especially the case for patients with steatohepatitis who are at the greatest risk of developing cirrhosis or liver cancer that can lead to liver failure. Due to the pathophysiological complexity of FLD and its diverse population, different therapeutic agents are likely to be needed in order to tackle the lipotoxic, inflammatory and fibrogenic effects seen in FLD.
Key Topics Covered:
1 Table of Contents
2 Executive Summary 2.1 Urgent Unmet Need Driven By Rising Prevalence 2.2 High Degree of First-in-Class Innovation 2.3 Rising Deal Volumes and Considerable Investment Opportunities in First-in-Class Product Development
3 The Case for Innovation 3.1 Growing Opportunities for Biologic Products 3.2 Diversification of Molecular Targets 3.3 Innovative First-in-Class Development Remains Attractive 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 3.5 Sustained Innovation 3.6 Research Report Guidance
8 Strategic Consolidations 8.1 Industry-Wide First-in-Class Deals 8.2 Licensing Deals 8.2.1 Deals by Region, Value and Year 8.2.2 Deals by Stage of Development and Value 8.2.3 Deals by Molecule Type, Molecular Target and Value 8.2.4 List of Deals with Disclosed Deal Values 8.3 Codevelopment Deals 8.3.1 Deals by Region, Value and Year 8.3.2 Deals by Stage of Development and Value 8.3.3 Deals by Molecule Type, Molecular Target and Value 8.3.4 List of Deals with Disclosed Deal Values 8.4 First-in-Class Programs with and without Prior Involvement in Licensing and Co-development Deals